Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Lee, Eun Young ^a   Park, Kyong Su ^a   Yoon, Yae Jin ^a   Lee, Jaewook ^a   Moon, Hyung Geun ^a   Jang, Su Chul ^a   Choi, Kyoung Ho ^b   Kim, Yoon Keun ^a   Gho, Yong Song ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; AUTOANTIGEN; AUTOLOGOUS TUMOR DERIVED NANOVESICLE VACCINE; CANCER VACCINE; UNCLASSIFIED DRUG; NANOPARTICLE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER TISSUE; CELL MATURATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; SKIN CANCER; SKIN MELANOMA; TUMOR IMMUNITY; ULTRASOUND; ANIMAL; C57BL MOUSE; EXOSOME; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; DENDRITIC CELLS; EXOSOMES; FEMALE; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; VACCINATION;

EID: 84863292705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033330     Document Type: Article

References (33)

1. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, et al. (2002) Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188: 97-113.
2. Emens LA, (2006) Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25: 415-443.
3. Gilboa E, (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
4. Pisani P, Parkin DM, Munoz N, Ferlay J, (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6: 387-400.
5. Mocellin S, Rossi CR, Nitti D, (2004) Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 299: 267-278.
6. Finn OJ, (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3: 630-641.
7. Hodi FS, (2006) Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res 12: 673-678.
8. Altin JG, Parish CR, (2006) Liposomal vaccines-targeting the delivery of antigen. Methods 40: 39-52.
9. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, et al. (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62: 2347-2352.
10. Prehn RT, Main JM, (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769-778.
11. Gercovich FG, Gutterman JU, Mavligit GM, Hersh EM, (1975) Active specific immunization in malignant melanoma. Med Pediatr Oncol 1: 277-287.
12. van Elsas A, Hurwitz AA, Allison JP, (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366.
13. Bachmann MF, Jennings GT, (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796.
14. Peek LJ, Middaugh CR, Berkland C, (2008) Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60: 915-928.
15. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA, (2006) In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 112: 26-34.
16. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303.
17. Thery C, Zitvogel L, Amigorena S, (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
18. Andre F, Schartz NE, Chaput N, Flament C, Raposo G, et al. (2002) Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 (Suppl 4): A28-31.
19. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, et al. (2004) Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104: 3257-3266.
20. Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, et al. (2002) Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 122: 282-288.
21. Yu X, Harris SL, Levine AJ, (2006) The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 66: 4795-4801.
22. Choi DS, Lee JM, Park GW, Lim HW, Bang JY, et al. (2007) Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 6: 4646-4655.
23. Thery C, Amigorena S, Raposo G, Clayton A, (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3 Unit 3 22.
24. Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, et al. (1999) Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 163: 57-61.
25. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, et al. (2008) Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 68: 1228-1235.
26. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, et al. (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190: 617-627.
27. Steinman RM, Pope M, (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109: 1519-1526.
28. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, et al. (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600.
29. Kovar M, Boyman O, Shen X, Hwang I, Kohler R, et al. (2006) Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. Proc Natl Acad Sci U S A 103: 11671-11676.
30. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, et al. (2009) Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124: 2621-2633.
31. Kotera Y, Shimizu K, Mule JJ, (2001) Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61: 8105-8109.
32. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, et al. (2007) VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 104: 2837-2842.
33. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.